Consequently, targeting CXCR4 signaling via e.g., CXCR4 antagonists, is a potent strategy for disrupting the influence of the protective microenvironment thus enhancing the efficacy of chemotherapy in AML (29–31). Here, CXCR4 is linked to acute myeloid leukemia.